Liquid pharmaceutical composition for the delivery of active ingredients

Patent metadata

Field	Value
Publication number	US-9757459-B2
Application number	US-201113824048-A
Country	US
Kind code	B2
Filing date	Oct 18, 2011
Priority date	Oct 20, 2010
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition in the form of a suspension comprising a dispersed phase in a liquid continuous phase wherein:
(a) The dispersed phase comprises solid particles of an active ingredient, wherein said active ingredient is selected from the group consisting of antibiotic agents, antifungal agents, corticoid, non-steroidal anti-inflammatory agents, and antiviral agents, said ingredient being present in a therapeutically effective amount, and
(b) the liquid continuous phase comprises a liquid vehicle comprising a semifluorinated alkane selected from F4H5, F4H6, F6H6 and F6H8;
wherein the composition is substantially free of water, and wherein the particles of the active ingredient have a volume mean diameter as, measured by laser diffraction of not more than about 15 μm.

2. The composition of claim 1 , being substantially free of surfactant.

3. The composition of claim 1 , wherein the active ingredient is poorly water-soluble and/or sensitive to hydrolytic degradation.

4. The composition of claim 3 , wherein the active ingredient exhibits a water solubility of less than about 1 mg per ml, as measured at room temperature and neutral pH.

5. The composition of claim 1 , further comprising anon-fluorinated organic liquid.

6. The composition of claim 1 , wherein the liquid vehicle has a refractive index in the range from 1.29 to 1.35 at 20° C.

7. A method of treating a disease or condition of the eye in a patient in need thereof, comprising administering to the eye the pharmaceutical composition of claim 1 , wherein the active ingredient is selected from the group consisting of antibiotic agents, antifungal agents, corticoid, non-steroidal anti-inflammatory agents, and antiviral agents, wherein said disease or condition is amenable to treatment with said active agent.

8. The method of claim 7 , wherein the pharmaceutical composition is a topical ophthalmic composition.

9. The method of claim 7 , wherein the pharmaceutical composition is administered by locoregional injection.

10. A container comprising the composition of claim 1 and a dispensing means adapted for topically administering the composition to the eye of a patient.

11. The method of claim 8 , wherein the composition comprises: an antibiotic agent selected from ofloxacin, ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin, gentamycin, tobramycin, chloramphenicol, polymyxin B, neomycin, kanamycin, erythyromycin and fusidic acid; or an antifungal agent which is amphotericin B; or a corticoid selected from fluorometholone, prednisolone and dexamethasone; or a non-steroidal anti-inflammatory agent selected from ibuprofen, indomethacin and flurbiprofen; or an antiviral agent which is ganciclovir.

12. The composition of claim 1 , wherein the antibiotic agent is selected from ciprofloxacin, levofloxacin, gentamycin, tobramycin, ofloxacin, lomefloxacin, moxifloxacin, chloramphenicol, polymyxin B, neomycin, kanamycin, erythromycin, and fusidic acid.

13. The composition of claim 1 , comprising not more than about 5 wt.-% surfactant.

14. The composition of claim 1 , wherein the composition is water-free.

15. The composition of claim 3 , wherein the active ingredient is selected from the group consisting of antifungal agents, corticoids, non-steroidal anti-inflammatory agents, and antiviral agents.

16. The composition of claim 15 , wherein the antifungal agent is amphotericin B.

17. The composition of claim 15 , wherein the corticoid is selected from the group consisting of fluorometholone, prednisolone and dexamethasone.

18. The composition of claim 15 , wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, indomethacin and flurbiprofen.

19. The composition of claim 15 , wherein the antiviral agent is ganciclovir.

20. A container according to claim 10 , wherein the dispensing means is adapted to dispense the composition dropwise in volumes of less than about 30 μl.

Assignees

• Theisinger Bastian
• Theisinger Sonja
• Günther Bernhard
• Novaliq Gmbh

Inventors

• Theisinger Bastian
• Theisinger Sonja
• Günther Bernhard

Classifications

• A61K9/0046

  Ear · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K47/06 Primary

  Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite · CPC title

• A61K9/0043

  Nose · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title